Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Arsenic trioxide + Tretinoin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Arsenic trioxide||Trisenox||ATO||GLI1/2 inhibitor 6||Trisenox (arsenic trioxide) has multiple mechanisms of action, including inhibition of Gli1 and Gli2 transcription factors (PMID: 26891329). Trisenox (arsenic trioxide) is FDA approved for patients with acute promyelocytic leukemia with PML-RARA translocations (FDA.gov).|
|Tretinoin||Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA||Tretinoin is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Tretinoin is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute promyelocytic leukemia||not applicable||Arsenic trioxide + Tretinoin||Phase III||Actionable||In a Phase III trial, a 40.6 month follow-up of acute promyelocytic leukemia (APL) patients treated with the combination of Vesanoid (tretinoin) and Trisenox (arsenic trioxide) demonstrated a better event-free survival, cumulative incidence of relapse, and overall survival when compared to APL patients treated with the combination of Vesanoid (tretinoin) and chemotherapy (PMID: 27400939).||27400939|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|